Transdermal Opportunity Zosano specializes in proprietary transdermal delivery to enable rapid onset of action for existing drugs. This creates a potential sales angle with CNS and acute symptom relief indications where fast delivery can improve patient outcomes and adherence.

Acute Care Focus Target markets include conditions requiring rapid symptom relief and improved convenience over oral or injectable options. Engage with hospitals, clinics, and long-term care facilities seeking faster-acting therapies with stable room-temperature formulations.

Small Team Agility With a lean workforce (11-50 employees), emphasize streamlined collaboration and quick pilot programs. Propose scalable partnerships, licensing, or co-development deals to accelerate market entry for new formulations.

Public Funding Readiness Recent financing activity and equity offerings indicate investor appetite and potential for partnerships. Leverage this to propose co-funding, grant-friendly programs, or milestone-based collaborations to de-risk early commercialization.

Portfolio Expansion There is potential to pair the transdermal system with a broader range of established drugs in CNS and other fast-onset needs. Propose strategic collaborations with pharma companies seeking enhanced delivery profiles and patient-friendly administration.